Cargando…

A dose-escalating toxicology study of the candidate biologic ELP-VEGF

Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and vascular repair, is reduced in chronic ischemic renal diseases, leading to microvascular rarefaction and deterioration of renal function. We developed a chimeric fusion of human VEGF-A(121) with the carrier protein Elastin...

Descripción completa

Detalles Bibliográficos
Autores principales: Waller, Jamarius P., Burke, Stephen P., Engel, Jason, Chade, Alejandro R., Bidwell, Gene L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973730/
https://www.ncbi.nlm.nih.gov/pubmed/33737643
http://dx.doi.org/10.1038/s41598-021-85693-6
_version_ 1783666882405990400
author Waller, Jamarius P.
Burke, Stephen P.
Engel, Jason
Chade, Alejandro R.
Bidwell, Gene L.
author_facet Waller, Jamarius P.
Burke, Stephen P.
Engel, Jason
Chade, Alejandro R.
Bidwell, Gene L.
author_sort Waller, Jamarius P.
collection PubMed
description Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and vascular repair, is reduced in chronic ischemic renal diseases, leading to microvascular rarefaction and deterioration of renal function. We developed a chimeric fusion of human VEGF-A(121) with the carrier protein Elastin-like Polypeptide (ELP-VEGF) to induce therapeutic angiogenesis via targeted renal VEGF therapy. We previously showed that ELP-VEGF improves renal vascular density, renal fibrosis, and renal function in swine models of chronic renal diseases. However, VEGF is a potent cytokine that induces angiogenesis and increases vascular permeability, which could cause undesired off-target effects or be deleterious in a patient with a solid tumor. Therefore, the current study aims to define the toxicological profile of ELP-VEGF and assess its risk for exacerbating tumor progression and vascularity using rodent models. A dose escalating toxicology assessment of ELP-VEGF was performed by administering a bolus intravenous injection at doses ranging from 0.1 to 200 mg/kg in Sprague Dawley (SD) rats. Blood pressure, body weight, and glomerular filtration rate (GFR) were quantified longitudinally, and terminal blood sampling and renal vascular density measurements were made 14 days after treatment. Additionally, the effects of a single administration of ELP-VEGF (0.1–10 mg/kg) on tumor growth rate, mass, and vascular density were examined in a mouse model of breast cancer. At doses up to 200 mg/kg, ELP-VEGF had no effect on body weight, caused no changes in plasma or urinary markers of renal injury, and did not induce renal fibrosis or other histopathological findings in SD rats. At the highest doses (100–200 mg/kg), ELP-VEGF caused an acute, transient hypotension (30 min), increased GFR, and reduced renal microvascular density 14 days after injection. In a mouse tumor model, ELP-VEGF did not affect tumor growth rate or tumor mass, but analysis of tumor vascular density by micro-computed tomography (μCT) revealed significant, dose dependent increases in tumor vascularity after ELP-VEGF administration. ELP-VEGF did not induce toxicity in the therapeutic dosing range, and doses one hundred times higher than the expected maximum therapeutic dose were needed to observe any adverse signs in rats. In breast tumor—bearing mice, ELP-VEGF therapy induced a dose-dependent increase in tumor vascularity, demanding caution for potential use in a patient suffering from kidney disease but with known or suspected malignancy.
format Online
Article
Text
id pubmed-7973730
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79737302021-03-19 A dose-escalating toxicology study of the candidate biologic ELP-VEGF Waller, Jamarius P. Burke, Stephen P. Engel, Jason Chade, Alejandro R. Bidwell, Gene L. Sci Rep Article Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis and vascular repair, is reduced in chronic ischemic renal diseases, leading to microvascular rarefaction and deterioration of renal function. We developed a chimeric fusion of human VEGF-A(121) with the carrier protein Elastin-like Polypeptide (ELP-VEGF) to induce therapeutic angiogenesis via targeted renal VEGF therapy. We previously showed that ELP-VEGF improves renal vascular density, renal fibrosis, and renal function in swine models of chronic renal diseases. However, VEGF is a potent cytokine that induces angiogenesis and increases vascular permeability, which could cause undesired off-target effects or be deleterious in a patient with a solid tumor. Therefore, the current study aims to define the toxicological profile of ELP-VEGF and assess its risk for exacerbating tumor progression and vascularity using rodent models. A dose escalating toxicology assessment of ELP-VEGF was performed by administering a bolus intravenous injection at doses ranging from 0.1 to 200 mg/kg in Sprague Dawley (SD) rats. Blood pressure, body weight, and glomerular filtration rate (GFR) were quantified longitudinally, and terminal blood sampling and renal vascular density measurements were made 14 days after treatment. Additionally, the effects of a single administration of ELP-VEGF (0.1–10 mg/kg) on tumor growth rate, mass, and vascular density were examined in a mouse model of breast cancer. At doses up to 200 mg/kg, ELP-VEGF had no effect on body weight, caused no changes in plasma or urinary markers of renal injury, and did not induce renal fibrosis or other histopathological findings in SD rats. At the highest doses (100–200 mg/kg), ELP-VEGF caused an acute, transient hypotension (30 min), increased GFR, and reduced renal microvascular density 14 days after injection. In a mouse tumor model, ELP-VEGF did not affect tumor growth rate or tumor mass, but analysis of tumor vascular density by micro-computed tomography (μCT) revealed significant, dose dependent increases in tumor vascularity after ELP-VEGF administration. ELP-VEGF did not induce toxicity in the therapeutic dosing range, and doses one hundred times higher than the expected maximum therapeutic dose were needed to observe any adverse signs in rats. In breast tumor—bearing mice, ELP-VEGF therapy induced a dose-dependent increase in tumor vascularity, demanding caution for potential use in a patient suffering from kidney disease but with known or suspected malignancy. Nature Publishing Group UK 2021-03-18 /pmc/articles/PMC7973730/ /pubmed/33737643 http://dx.doi.org/10.1038/s41598-021-85693-6 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Waller, Jamarius P.
Burke, Stephen P.
Engel, Jason
Chade, Alejandro R.
Bidwell, Gene L.
A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_full A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_fullStr A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_full_unstemmed A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_short A dose-escalating toxicology study of the candidate biologic ELP-VEGF
title_sort dose-escalating toxicology study of the candidate biologic elp-vegf
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973730/
https://www.ncbi.nlm.nih.gov/pubmed/33737643
http://dx.doi.org/10.1038/s41598-021-85693-6
work_keys_str_mv AT wallerjamariusp adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT burkestephenp adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT engeljason adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT chadealejandror adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT bidwellgenel adoseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT wallerjamariusp doseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT burkestephenp doseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT engeljason doseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT chadealejandror doseescalatingtoxicologystudyofthecandidatebiologicelpvegf
AT bidwellgenel doseescalatingtoxicologystudyofthecandidatebiologicelpvegf